TY - JOUR
T1 - A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer
AU - Totani, Yoshitaka
AU - Saito, Yuji
AU - Hayashi, Masamichi
AU - Tada, Toshihiko
AU - Kohashi, Yasuo
AU - Mieno, Yuki
AU - Kato, Atsushi
AU - Imizu, Hiromi
AU - Yoneda, Yukiko
AU - Hoshino, Tami
AU - Uchiyama, Yasuhiro
AU - Takeuchi, Yasuo
AU - Okazawa, Mitsushi
AU - Sakakibara, Hiroki
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/11
Y1 - 2009/11
N2 - Purpose: To assess the efficacy and toxicity of an oral anticancer fluoropyrimidine derivative, S-1, for previously treated patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Patients with advanced (clinical stage IIIB-IV) NSCLC who had previously received one platinum-based chemotherapy were enrolled. S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b.i.d. for 28 consecutive days, repeated every 6 weeks. Results: Between August 2005 and July 2007, 50 patients were entered into this study. Six patients achieved partial response (PR), and the overall response rate of eligible patients was 12.5% (6/48) (95% confidence interval (95%CI), 3.1-21.9%). Disease control rate was 39.6% (19/48) (95%CI, 25.7-53.4%). Median progression-free survival was 2.5 months. Median survival time was 8.2 months, and 1-year survival rate was 29.6%. No grade 4 toxicities were encountered. Grade 3 hematological toxicities comprised neutropenia in one patient (2.1%) and anemia in one patient (2.1%). Grade 3 non-hematological toxicities were observed in only five patients (10.4%). Treatment-related death did not occur. Conclusion: S-1 is an active and well-tolerated monotherapy for second-line treatment of advanced NSCLC.
AB - Purpose: To assess the efficacy and toxicity of an oral anticancer fluoropyrimidine derivative, S-1, for previously treated patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Patients with advanced (clinical stage IIIB-IV) NSCLC who had previously received one platinum-based chemotherapy were enrolled. S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b.i.d. for 28 consecutive days, repeated every 6 weeks. Results: Between August 2005 and July 2007, 50 patients were entered into this study. Six patients achieved partial response (PR), and the overall response rate of eligible patients was 12.5% (6/48) (95% confidence interval (95%CI), 3.1-21.9%). Disease control rate was 39.6% (19/48) (95%CI, 25.7-53.4%). Median progression-free survival was 2.5 months. Median survival time was 8.2 months, and 1-year survival rate was 29.6%. No grade 4 toxicities were encountered. Grade 3 hematological toxicities comprised neutropenia in one patient (2.1%) and anemia in one patient (2.1%). Grade 3 non-hematological toxicities were observed in only five patients (10.4%). Treatment-related death did not occur. Conclusion: S-1 is an active and well-tolerated monotherapy for second-line treatment of advanced NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=69049087656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69049087656&partnerID=8YFLogxK
U2 - 10.1007/s00280-009-0981-1
DO - 10.1007/s00280-009-0981-1
M3 - Article
C2 - 19377885
AN - SCOPUS:69049087656
SN - 0344-5704
VL - 64
SP - 1181
EP - 1185
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 6
ER -
